Here are the latest stories being discussed in biopharma today:

1. Jaguar Gene Therapy is to create a separate company, Advanced Medicine Partners, to carry out its chemistry, manufacturing and controls operations. It is supported in this endeavor by Deerfield, ARCH Venture Partners and Nolan Capital. The company will take over Jaguar’s facility in North Carolina which is currently under construction. It plans to start clinical manufacturing in 2025.

2. The US Patent and Trademark Office has dismissed Seagen’s allegations of patent infringement by Daiichi Sankyo, in which Seagen contended that its ADC linker technology had been used by Daiichi in its products, such as the distribution of AstraZeneca-partnered Enheru.

3. Dewpoint Therapeutics will cut 15% of its staff as it prepares for its first clinical trials next year in colorectal cancer and amyotrophic lateral sclerosis (ALS) as it moves from a discovery-stage startup to a drug development company. However, no condensate scientists and experts will be affected.

4. Tr1x, a Treg cell therapy startup, has emerged from stealth mode with $75 million in funding. The company aims to ‘trick’ helper T cells into becoming Tr1-like through cell engineering by developing an off-the shelf therapy. The